Cargando…

Expression of MDR1/P glycoprotein in human sarcomas.

Conflicting reports of MDR1 gene expression in human tumours are observed according to whether studies are performed at the mRNA or P-glycoprotein level. We have investigated this expression in 22 clinically drug-resistant sarcomas at the mRNA level by Northern blot (NB), Dot blot (DB), in situ hybr...

Descripción completa

Detalles Bibliográficos
Autores principales: Vergier, B., Cany, L., Bonnet, F., Robert, J., de Mascarel, A., Coindre, J. M.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1993
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968648/
https://www.ncbi.nlm.nih.gov/pubmed/7903154
_version_ 1782134786326790144
author Vergier, B.
Cany, L.
Bonnet, F.
Robert, J.
de Mascarel, A.
Coindre, J. M.
author_facet Vergier, B.
Cany, L.
Bonnet, F.
Robert, J.
de Mascarel, A.
Coindre, J. M.
author_sort Vergier, B.
collection PubMed
description Conflicting reports of MDR1 gene expression in human tumours are observed according to whether studies are performed at the mRNA or P-glycoprotein level. We have investigated this expression in 22 clinically drug-resistant sarcomas at the mRNA level by Northern blot (NB), Dot blot (DB), in situ hybridisation (ISH), and at the protein level by immunohistochemistry (IHC) using three monoclonal antibodies (MoAbs): C219, JSB1, MRK16. Increased MDR1 mRNA expression was detected by NB, DB, and ISH in 1/22 sarcoma (an Ewing's sarcoma). ISH was perfectly correlated with DB hybridisation and confirmed the expression of tumoral cells alone. Specific staining of 100% of tumoral cells was obtained with the three MoAbs in the same sarcoma. Expression in tumoral cells of 12 other sarcomas was detected with MRK16, and positive staining of stromal cells with both C219 (1/22) and MRK16 (8/22) was observed. This study confirms that MDR1 overexpression occurs in human sarcomas but is not the principal mechanism of drug-resistance. Furthermore, positivity with one antibody does not necessarily imply the presence of P glycoprotein (P-gp) and a disparity may exist between the levels of P-gp and its mRNA in the same sample. So care must be taken in interpreting results and more sensitive techniques such as the polymerase chain reaction (PCR) could prove useful. IMAGES:
format Text
id pubmed-1968648
institution National Center for Biotechnology Information
language English
publishDate 1993
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19686482009-09-10 Expression of MDR1/P glycoprotein in human sarcomas. Vergier, B. Cany, L. Bonnet, F. Robert, J. de Mascarel, A. Coindre, J. M. Br J Cancer Research Article Conflicting reports of MDR1 gene expression in human tumours are observed according to whether studies are performed at the mRNA or P-glycoprotein level. We have investigated this expression in 22 clinically drug-resistant sarcomas at the mRNA level by Northern blot (NB), Dot blot (DB), in situ hybridisation (ISH), and at the protein level by immunohistochemistry (IHC) using three monoclonal antibodies (MoAbs): C219, JSB1, MRK16. Increased MDR1 mRNA expression was detected by NB, DB, and ISH in 1/22 sarcoma (an Ewing's sarcoma). ISH was perfectly correlated with DB hybridisation and confirmed the expression of tumoral cells alone. Specific staining of 100% of tumoral cells was obtained with the three MoAbs in the same sarcoma. Expression in tumoral cells of 12 other sarcomas was detected with MRK16, and positive staining of stromal cells with both C219 (1/22) and MRK16 (8/22) was observed. This study confirms that MDR1 overexpression occurs in human sarcomas but is not the principal mechanism of drug-resistance. Furthermore, positivity with one antibody does not necessarily imply the presence of P glycoprotein (P-gp) and a disparity may exist between the levels of P-gp and its mRNA in the same sample. So care must be taken in interpreting results and more sensitive techniques such as the polymerase chain reaction (PCR) could prove useful. IMAGES: Nature Publishing Group 1993-12 /pmc/articles/PMC1968648/ /pubmed/7903154 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Vergier, B.
Cany, L.
Bonnet, F.
Robert, J.
de Mascarel, A.
Coindre, J. M.
Expression of MDR1/P glycoprotein in human sarcomas.
title Expression of MDR1/P glycoprotein in human sarcomas.
title_full Expression of MDR1/P glycoprotein in human sarcomas.
title_fullStr Expression of MDR1/P glycoprotein in human sarcomas.
title_full_unstemmed Expression of MDR1/P glycoprotein in human sarcomas.
title_short Expression of MDR1/P glycoprotein in human sarcomas.
title_sort expression of mdr1/p glycoprotein in human sarcomas.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968648/
https://www.ncbi.nlm.nih.gov/pubmed/7903154
work_keys_str_mv AT vergierb expressionofmdr1pglycoproteininhumansarcomas
AT canyl expressionofmdr1pglycoproteininhumansarcomas
AT bonnetf expressionofmdr1pglycoproteininhumansarcomas
AT robertj expressionofmdr1pglycoproteininhumansarcomas
AT demascarela expressionofmdr1pglycoproteininhumansarcomas
AT coindrejm expressionofmdr1pglycoproteininhumansarcomas